BURST CME™: What Is the Real Risk in Lower-Risk MDS?
BURST CME™: What Is the Real Risk in Lower-Risk MDS? is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 23, 2023
Expiration Date: March 23, 2024
Description:
Lower-risk myelodysplastic syndromes (LR-MDS) comprise a heterogeneous set of hematologic malignancies characterized by hallmark cytopenias that can lead to a significant transfusion burden. New treatment options and best practices are poised to alter the standard of care for LR-MDS.
This activity focuses on the evolving best practices for risk stratification, which may help to delineate patients with classically LR-MDS who should be managed more aggressively to preserve outcomes. This material is supplemented by interviews with expert faculty who provide current management and insights into new treatment approaches to LR-MDS.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
Examine current methods to manage lower-risk myelodysplastic syndromes (LR-MDS) and unmet clinical needs in the field
Describe evolving treatment goals among patients with LR-MDS and emerging approaches for its management
Explain recent trial data and ongoing investigations evaluating novel strategies to treat patients with LR-MDS.
